echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Next month, GlaxoSmithKline's breathing lines will merge

    Next month, GlaxoSmithKline's breathing lines will merge

    • Last Update: 2021-02-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    has been a core therapeutic area for many multinational pharmaceutical companies for more than a decade, but this year there have been a number of changes, starting tonight with GlaxoSmithKline's latest tweak.GSK last week breathing line news today has been officially informed, GlaxoSmithKline China has officially informed employees, from May 1, the respiratory business structure adjustment, specifically, the original innovative products and classic products combined, the entire breathing team divided into two regional management centers in South and North China.specific person in charge has also announced that Li Guofeng, now the national business head of innovative products, is in charge of the north China respiratory business, and Lin Ziming, the national business director of classic products, is in charge of the south China region breathing business.Under this change, the innovative product business is fully re-entered into the classic product business Shulidi's sales team, to carry out collaborative academic promotion, and at the end of last year just entered the new version of the national health insurance directory, Ou Lexin, set up a full-time sales team to promote.understands that this architectural consolidation has no impact on most delegate and regional manager jurisdictions.▌ One year, back to the big breathing line At this time a year ago, GSK China separated the new and old products of the respiratory business unit, restructured the prescription drug business segment, and established the Innovative Products Business Unit and the Classic Products Business Unit, among which the Innovative Products Business Unit This includes two breathing new drugs, Quanre and Oli Xin, under the responsibility of Chen Siyuan (who has left GSK and is currently the general manager of Shiguibao China), and the Classic Products business unit has Shu Lidi, Wan Ruishu and the hepatitis portfolio.For the changes of multinational pharmaceutical companies in recent years, if you pay attention to the daily sharing, you should be able to see that in order to cope with the changes in the market, this two years, a number of multinational pharmaceutical companies have chosen to promote mature drugs and innovative drugs separately, I believe GSK China a year ago this decision, should also be out of this aspect of consideration.The domestic pharmaceutical market changed too much last year, whether it is the expansion of the national drug belt collection and the promotion of the second batch of national mining, or the introduction of a new version of the national health insurance catalog, have a huge impact on the pharmaceutical company's product layout, coupled with the impact of the epidemic on the promotion of new products, but also inspired a lot of changes, take GSK, Olexin into health insurance, Wan Ruishu out, decided the two products different outcomes.GSK's slow-blocking lung therapy drug Ome bromide/Virantero Inhalation Powder Mist was approved in China in March 2018 and included in the new health insurance catalog by the end of 2019, while GSK's other drug for ROMD treatment, Omelfon (fluorotimide inhalation powder mist), was also approved in China at this time.the restructuring announced today is also a positive response to market changes. (Medical representative)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.